Disclosure Under Regulation 30 of SEBI Listing Regulations

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.9%Reaction day

₹329.25

prior close

₹325.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.7%-1.2% vs market

Pharmaceuticals peers, median of 151sector-0.8%-1.1% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.2

15m

+0.4

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.9-0.7-1.2-0.8-1.1

Next day

-4.0-2.3-1.7-2.8-1.2

-4.3-1.8-2.5-2.2-2.0

-3.9-2.1-1.8-2.9-1.1

-6.8-3.2-3.6-4.7-2.0

-11.3-3.5-7.8-4.1-7.3

-18.1-4.1-14.0-4.2-13.9

15d

-22.2-2.0-20.2-3.6-18.5

-22.1-3.4-18.7-4.7-17.4

-23.7-5.1-18.6-6.7-17.0

-27.4-1.3-26.1-6.0-21.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hikal Limited has received a Good Manufacturing Practices (GMP) certificate from Japan's Pharmaceutical and Medical Device Agency (PMDA) for its Jigani (Bangalore Unit-1) API manufacturing facility. The PMDA had inspected the plant from May 19-22, 2025, and the site at KIADB Industrial Area, Jigani, Bangalore has now been confirmed compliant with Japanese GMP guidelines. This certification allows the company to manufacture and supply active pharmaceutical ingredients to the Japanese market, which is one of the world's largest pharmaceutical markets. The company has disclosed this under SEBI Listing Regulation 30.

Likely market impact

Positive for shareholders — PMDA GMP certification opens the door to the high-value Japanese pharmaceutical market for Hikal's API business, potentially driving future export revenue growth and strengthening the company's global regulatory footprint.